Approval allows for use in nonambulatory individuals ≥4 years with a confirmed gene mutation
MONDAY, June 24, 2024 (HealthDay News) — The U.S. Food and Drug Administration has expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) in individuals ≥4 years with DMD with a confirmed mutation in the DMD gene.
Elevidys is a single-dose, intravenous recombinant gene therapy designed to produce Elevidys micro-dystrophin, a shortened protein (138 kDa, versus the 427 kDa dystrophin protein of normal muscle cells) that contains selected domains of the dystrophin protein present in normal muscle cells.
The FDA granted traditional approval for ambulatory individuals ≥4 years with DMD with a confirmed mutation in the DMD gene, as well as accelerated approval in nonambulatory individuals ≥4 years. The traditional approval was based on two double-blind, placebo-controlled studies and two open-label studies (a total of 218 male participants). While the trial Elevidys failed to meet its primary end point of improvement in the North Star Ambulatory Assessment versus placebo, it did meet key secondary outcome measures (time to rise from the floor, 10-meter walk/run, time to ascend four steps, and creatine kinase levels). The FDA determined that “increased levels in micro-dystrophin is reasonably likely to predict clinical benefit in the nonambulatory population,” supporting the accelerated approval in nonambulatory individuals. The most commonly reported side effects with Elevidys included nausea and vomiting, acute liver injury, fever, and thrombocytopenia.
“Today”s approval broadens the spectrum of patients with Duchenne muscular dystrophy eligible for this therapy, helping to address the ongoing, urgent treatment need for patients with this devastating and life-threatening disease,” Peter Marks, M.D., Ph.D., from the FDA Center for Biologics Evaluation and Research, said in a statement.
Expanded approval of Elevidys was granted to Sarepta Therapeutics.
BIND Screener Can ID Brain-Related Comorbidities in Duchenne Muscular Dystrophy 
Most Speakers at FDA Advisory Committee Meetings Support Drug Approval 
Countries Involved in U.S. Clinical Trials Do Not Gain Timely Access to Approved Medicines 
FDA Picks George Tidmarsh to Head Center for Drug Evaluation and Research 
FDA Sends 100 Cease-and-Desist Letters in Crackdown on DTC Drug Advertisements 
FDA Creates "Green List" of GLP-1 Drug Ingredients Approved for Entry in the U.S. 
FDA Suspends U.S. License of Chikungunya Vaccine 
